---
title: "Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295123994.md"
description: "Takeda received FDA approval for Orzeyful (oveporexton), the first oral orexin receptor 2 agonist for treating narcolepsy type 1 in adults. This holistic treatment addresses the root cause by activating brain receptors rather than just masking symptoms, based on positive Phase 3 trial data. The Drug Enforcement Administration is currently reviewing its controlled substance classification, with availability expected via specialty pharmacies upon completion."
datetime: "2026-08-06T15:16:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295123994.md)
  - [en](https://longbridge.com/en/news/295123994.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295123994.md)
generator: "portal-rs"
---

# Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Ta**keda Pharmaceutical Co. Ltd.**‘s (NYSE:TAK) Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.

This oral orexin receptor 2 agonist marks the first treatment of its kind designed to address the condition comprehensively rather than just managing specific symptoms.

## Comprehensive Approach To Narcolepsy Type 1

Narcolepsy type 1 is a rare neurological disorder caused by an orexin shortage. It currently impacts roughly 120,000 individuals in the U.S.

Patients often suffer from extreme daytime drowsiness, sudden muscle weakness known as cataplexy, cognitive challenges, and fragmented nighttime rest, which can severely disrupt daily activities like work and social engagements.

 **Read Also: Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study** 

The regulatory clearance stems from robust data gathered during the global Phase 3 FirstLight and RadiantLight trials.

These studies demonstrated that oveporexton provided statistically meaningful enhancements across a broad spectrum of symptoms.

The FDA, in a press release, noted that rather than masking symptoms with stimulants or sedatives, Orzeyful directly activates the same brain receptor that the body’s own orexin would normally stimulate, restoring the missing signal.

## Future Availability

Currently, the Drug Enforcement Administration is assessing the drug for controlled substance classification, a process anticipated to conclude within 90 days.

Following this determination, the medication will roll out to healthcare providers and patients via a specialty pharmacy.

TAK Stock Price Activity: Takeda Pharmaceutical Co shares were up 1.38% at $16.95 at the time of publication on Thursday, according to Benzinga Pro data.

*Photo by Tada Images via Shutterstock*

 **Read Also: SanDisk Breaks the Boom‑Bust Cycle With Four‑Year Visibility**

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)
- [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md)

## Related News & Research

- [Takeda CHRO Nicola D. Greenway sells 12,980 ADS for $235,173.42](https://longbridge.com/en/news/296395853.md)
- [FDA Approves First Drug To Treat Narcolepsy Type 1 Symptoms](https://longbridge.com/en/news/295106426.md)
- [Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock](https://longbridge.com/en/news/295785108.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection](https://longbridge.com/en/news/296165366.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**